Triple-negative/basal-like breast cancer: review

References

• Edwards B K, Brown M L, Wingo P A, et al. Annual report to the nation on the status of cancer, 1975–2002, featuring population-based trends in cancer treatment. J Natl Cancer Inst 2005; 97: 1407–27
   PubMed Web of Science ®Google Scholar
• McGuire W L, Horwitz K B, Pearson O H, et al. Current status of estrogen and progesterone receptors in breast cancer. Cancer 1977; 39: 2934–47
   PubMed Web of Science ®Google Scholar
• Osborne C K, Yochmowitz M G, Knight W A, 3rd, et al. The value of estrogen and progesterone receptors in the treatment of breast cancer. Cancer 1980; 46: 2884–8
   PubMed Web of Science ®Google Scholar
• Rakha E A, El-Sayed M E, Green A R, et al. Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotype. J Clin Oncol 2007; 25: 4772–8
   PubMed Web of Science ®Google Scholar
• Rhodes A, Jasani B, Balaton A J, et al. Frequency of oestrogen and progesterone receptor positivity by immunohistochemical analysis in 7016 breast carcinomas: correlation with patient age, assay sensitivity, threshold value, and mammographic screening. J Clin Pathol 2000; 53: 688–96
   PubMed Web of Science ®Google Scholar
• Rakha E A, El-Sayed M E, Green A R, et al. Prognostic markers in triple-negative breast cancer. Cancer 2007; 109: 25–32
   PubMed Web of Science ®Google Scholar
• Putti T C, El-Rehim D M, Rakha E A, et al. Estrogen receptor-negative breast carcinomas: a review of morphology and immunophenotypical analysis. Mod Pathol 2005; 18: 26–35
   PubMed Web of Science ®Google Scholar
• Shao W, Brown M. Advances in estrogen receptor biology: prospects for improvements in targeted breast cancer therapy. Breast Cancer Res 2004; 6: 39–52
   PubMed Web of Science ®Google Scholar
• Slamon D J, Clark G M, Wong S G, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177–82
   PubMed Web of Science ®Google Scholar
• Wolff A C, Hammond M E, Schwartz J N, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007; 25: 118–45
   PubMed Web of Science ®Google Scholar
• Ross J S, Fletcher J A, Bloom K J, et al. Targeted therapy in breast cancer: the HER-2/neu gene and protein. Mol Cell Proteomics 2004; 3: 379–98
   PubMed Web of Science ®Google Scholar
• Piccart-Gebhart M J, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005; 353: 1659–72
   PubMed Web of Science ®Google Scholar
• Romond E H, Perez E A, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353: 1673–84
   PubMed Web of Science ®Google Scholar
• Dent R, Trudeau M, Pritchard K I, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 2007; 13: 4429–34
   PubMed Web of Science ®Google Scholar
• Haffty B G, Yang Q, Reiss M, et al. Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol 2006; 24: 5652–7
   PubMed Web of Science ®Google Scholar
• National Health Service Breast Screening Programme (NHSBSP) and The Royal College of Pathologists. Pathology Reporting of Breast Disease. NHSBSP and The Royal College of Pathologists, Sheffield 2005, NHSBSP Pub. No 58
   Google Scholar
• Perou C M, Sorlie T, Eisen M B, et al. Molecular portraits of human breast tumours. Nature 2000; 406: 747–52
   PubMed Web of Science ®Google Scholar
• Sorlie T, Perou C M, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001; 98: 10869–74
   PubMed Web of Science ®Google Scholar
• Sotiriou C, Wirapati P, Loi S, et al. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 2006; 98: 262–72
   PubMed Web of Science ®Google Scholar
• Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003; 100: 8418–23
   PubMed Web of Science ®Google Scholar
• Sotiriou C, Neo S Y, McShane L M, et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci USA 2003; 100: 10393–8
   PubMed Web of Science ®Google Scholar
• Carey L A, Dees E C, Sawyer L, et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 2007; 13: 2329–34
   PubMed Web of Science ®Google Scholar
• Kreike B, van Kouwenhove M, Horlings H, et al. Gene expression profiling and histopathological characterization of triple negative/basal-like breast carcinomas. Breast Cancer Res 2007; 9: R65
   PubMed Web of Science ®Google Scholar
• Jacquemier J, Padovani L, Rabayrol L, et al. Typical medullary breast carcinomas have a basal/myoepithelial phenotype. J Pathol 2005; 207: 260–8
   PubMed Web of Science ®Google Scholar
• Diaz L K, Cryns V L, Symmans W F, et al. Triple negative breast carcinoma and the basal phenotype: from expression profiling to clinical practice. Adv Anat Pathol 2007; 14: 419–30
   PubMed Web of Science ®Google Scholar
• Rouzier R, Perou C M, Symmans W F, et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 2005; 11: 5678–85
   PubMed Web of Science ®Google Scholar
• Calza S, Hall P, Auer G, et al. Intrinsic molecular signature of breast cancer in a population-based cohort of 412 patients. Breast Cancer Res 2006; 8: R34
   PubMed Web of Science ®Google Scholar
• Jumppanen M, Gruvberger-Saal S, Kauraniemi P, et al. Basal-like phenotype is not associated with patient survival in estrogen-receptor-negative breast cancers. Breast Cancer Res 2007; 9: R16
   PubMed Web of Science ®Google Scholar
• Bertucci F, Finetti P, Cervera N, et al. How basal are triple-negative breast cancers?. Int J Cancer 2008; 123: 236–40
   PubMed Web of Science ®Google Scholar
• Tischkowitz M, Brunet J S, Begin L R, et al. Use of immunohistochemical markers can refine prognosis in triple negative breast cancer. BMC Cancer 2007; 7: 134
   PubMed Web of Science ®Google Scholar
• Bidard F C, Conforti R, Boulet T, et al. Does triple-negative phenotype accurately identify basal-like tumour? An immunohistochemical analysis based on 143 ‘triple-negative’ breast cancers. Ann Oncol 2007; 18: 1285–6
   PubMed Web of Science ®Google Scholar
• Tan D S, Marchio C, Jones R L, et al. Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients. Breast Cancer Res Treat 2008; 111: 27–44
   PubMed Web of Science ®Google Scholar
• Lakhani S R, Reis-Filho J S, Fulford L, et al. Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clin Cancer Res 2005; 11: 5175–80
   PubMed Web of Science ®Google Scholar
• Rakha E A, El-Sayed M E, Green A R, et al. Breast carcinoma with basal differentiation: a proposal for pathology definition based on basal cytokeratin expression. Histopathology 2007; 50: 434–8
   PubMed Web of Science ®Google Scholar
• van de Rijn M, Perou C M, Tibshirani R, et al. Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome. Am J Pathol 2002; 161: 1991–6
   PubMed Web of Science ®Google Scholar
• Rakha E A, Tan D S, Foulkes W D, et al. Are triple negative tumours and basal-like breast cancer synonymous?. Breast Cancer Res 2007; 9: R80
   PubMed Web of Science ®Google Scholar
• Harris L N, You F, Schnitt S J, et al. Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer. Clin Cancer Res 2007; 13: 1198–207
   PubMed Web of Science ®Google Scholar
• Nielsen T O, Hsu F D, Jensen K, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004; 10: 5367–74
   PubMed Web of Science ®Google Scholar
• Rakha E A, Putti T C, Abd El-Rehim D M, et al. Morphological and immunophenotypic analysis of breast carcinomas with basal and myoepithelial differentiation. J Pathol 2006; 208: 495–506
   PubMed Web of Science ®Google Scholar
• Rody A, Karn T, Solbach C, et al. The erbB2+ cluster of the intrinsic gene set predicts tumor response of breast cancer patients receiving neoadjuvant chemotherapy with docetaxel, doxorubicin and cyclophosphamide within the GEPARTRIO trial. Breast 2007; 16: 235–40
   PubMed Web of Science ®Google Scholar
• Fan C, Oh D S, Wessels L, et al. Concordance among gene-expression-based predictors for breast cancer. N Engl J Med 2006; 355: 560–9
   PubMed Web of Science ®Google Scholar
• Teschendorff A E, Miremadi A, Pinder S E, et al. An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer. Genome Biol 2007; 8: R157
   PubMed Web of Science ®Google Scholar
• Diallo-Danebrock R, Ting E, Gluz O, et al. Protein expression profiling in high-risk breast cancer patients treated with high-dose or conventional dose-dense chemotherapy. Clin Cancer Res 2007; 13: 488–97
   PubMed Web of Science ®Google Scholar
• Carey L A, Perou C M, Livasy C A, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006; 295: 2492–502
   PubMed Web of Science ®Google Scholar
• Yang X R, Sherman M E, Rimm D L, et al. Differences in risk factors for breast cancer molecular subtypes in a population-based study. Cancer Epidemiol Biomarkers Prev 2007; 16: 439–43
   PubMed Web of Science ®Google Scholar
• Liu H, Fan Q, Zhang Z, et al. Basal-HER2 phenotype shows poorer survival than basal-like phenotype in hormone receptor-negative invasive breast cancers. Hum Pathol 2008; 39: 167–74
   PubMed Web of Science ®Google Scholar
• Hu Z, Fan C, Oh D S, et al. The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics 2006; 7: 96
   PubMed Web of Science ®Google Scholar
• Scawn R, Shousha S. Morphologic spectrum of estrogen receptor-negative breast carcinoma. Arch Pathol Lab Med 2002; 126: 325–30
   PubMed Web of Science ®Google Scholar
• Cheang M C, Voduc D, Bajdik C, et al. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res 2008; 14: 1368–76
   PubMed Web of Science ®Google Scholar
• Sasa M, Bando Y, Takahashi M, et al. Screening for basal marker expression is necessary for decision of therapeutic strategy for triple-negative breast cancer. J Surg Oncol 2008; 97: 30–34
   PubMed Web of Science ®Google Scholar
• Dabbs D J, Chivukula M, Carter G, et al. Basal phenotype of ductal carcinoma in situ: recognition and immunohistologic profile. Mod Pathol 2006; 19: 1506–11
   PubMed Web of Science ®Google Scholar
• Foulkes W D, Grainge M J, Rakha E A, et al. Tumor size is an unreliable predictor of prognosis in basal-like breast cancers and does not correlate closely with lymph node status. Breast Cancer Res Treat 2008; Jul 4, (Epub ahead of print)
   Google Scholar
• Rakha E A, Reis-Filho J S, Ellis I O. Basal-like breast cancer: A critical review. J Clin Oncol 2008; 26: 2568–81
   PubMed Web of Science ®Google Scholar
• Rhodes A, Jasani B, Barnes D M, et al. Reliability of immunohistochemical demonstration of oestrogen receptors in routine practice: interlaboratory variance in the sensitivity of detection and evaluation of scoring systems. J Clin Pathol 2000; 53: 125–30
   PubMed Web of Science ®Google Scholar
• Turner N C, Reis-Filho J S, Russell A M, et al. BRCA1 dysfunction in sporadic basal-like breast cancer. Oncogene 2007; 26: 2126–32
   PubMed Web of Science ®Google Scholar
• Matos I, Dufloth R, Alvarenga M, et al. p63, cytokeratin 5, and P-cadherin: three molecular markers to distinguish basal phenotype in breast carcinomas. Virchows Arch 2005; 447: 688–94
   PubMed Web of Science ®Google Scholar
• Ribeiro-Silva A, Ramalho L N, Garcia S B, et al. p63 correlates with both BRCA1 and cytokeratin 5 in invasive breast carcinomas: further evidence for the pathogenesis of the basal phenotype of breast cancer. Histopathology 2000; 47: 458–66
   Web of Science ®Google Scholar
• Fulford L G, Reis-Filho J S, Ryder K, et al. Basal-like grade III invasive ductal carcinoma of the breast: patterns of metastasis and long-term survival. Breast Cancer Res 2007; 9: R4
   PubMed Web of Science ®Google Scholar
• Jones C, Ford E, Gillett C, et al. Molecular cytogenetic identification of subgroups of grade III invasive ductal breast carcinomas with different clinical outcomes. Clin Cancer Res 2004; 10: 5988–97
   PubMed Web of Science ®Google Scholar
• Laakso M, Loman N, Borg A, et al. Cytokeratin 5/14-positive breast cancer: true basal phenotype confined to BRCA1 tumors. Mod Pathol 2005; 18: 1321–8
   PubMed Web of Science ®Google Scholar
• Potemski P, Kusinska R, Watala C, et al. Prognostic relevance of basal cytokeratin expression in operable breast cancer. Oncology 2005; 69: 478–85
   PubMed Web of Science ®Google Scholar
• Foulkes W D, Brunet J S, Stefansson I M, et al. The prognostic implication of the basal-like (cyclin E high/p27 low/p53+/glomeruloid-microvascular-proliferation+) phenotype of BRCA1-related breast cancer. Cancer Res 2004; 64: 830–5
   PubMed Web of Science ®Google Scholar
• Banerjee S, Reis-Filho J S, Ashley S, et al. Basal-like breast carcinomas: clinical outcome and response to chemotherapy. J Clin Pathol 2006; 59: 729–35
   PubMed Web of Science ®Google Scholar
• Siziopikou K P, Cobleigh M. The basal subtype of breast carcinomas may represent the group of breast tumors that could benefit from EGFR-targeted therapies. Breast 2007; 16: 104–7
   PubMed Web of Science ®Google Scholar
• Rakha E A, El-Rehim D A, Paish C, et al. Basal phenotype identifies a poor prognostic subgroup of breast cancer of clinical importance. Eur J Cancer 2006; 42: 3149–56
   PubMed Web of Science ®Google Scholar
• Rodriguez-Pinilla S M, Sarrio D, Honrado E, et al. Vimentin and laminin expression is associated with basal-like phenotype in both sporadic and BRCA1-associated breast carcinomas. J Clin Pathol 2007; 60: 1006–12
   PubMed Web of Science ®Google Scholar
• Livasy C A, Perou C M, Karaca G, et al. Identification of a basal-like subtype of breast ductal carcinoma in situ. Hum Pathol 2007; 38: 197–204
   PubMed Web of Science ®Google Scholar
• Rodriguez-Pinilla S M, Sarrio D, Moreno-Bueno G, et al. Sox2: a possible driver of the basal-like phenotype in sporadic breast cancer. Mod Pathol 2007; 20: 474–81
   PubMed Web of Science ®Google Scholar
• Rodriguez-Pinilla S M, Rodriguez-Gil Y, Moreno-Bueno G, et al. Sporadic invasive breast carcinomas with medullary features display a basal-like phenotype: an immunohistochemical and gene amplification study. Am J Surg Pathol 2007; 31: 501–8
   PubMed Web of Science ®Google Scholar
• Pinilla S M, Honrado E, Hardisson D, et al. Caveolin-1 expression is associated with a basal-like phenotype in sporadic and hereditary breast cancer. Breast Cancer Res Treat 2006; 99: 85–90
   PubMed Web of Science ®Google Scholar
• Livasy C A, Karaca G, Nanda R, et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol 2006; 19: 264–71
   PubMed Web of Science ®Google Scholar
• Kim M J, Ro J Y, Ahn S H, et al. Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes. Hum Pathol 2006; 37: 1217–26
   PubMed Web of Science ®Google Scholar
• Rodriguez-Pinilla S M, Sarrio D, Honrado E, et al. Prognostic significance of basal-like phenotype and fascin expression in node-negative invasive breast carcinomas. Clin Cancer Res 2006; 12: 1533–9
   PubMed Web of Science ®Google Scholar
• Collett K, Stefansson I M, Eide J, et al. A basal epithelial phenotype is more frequent in interval breast cancers compared with screen detected tumors. Cancer Epidemiol Biomarkers Prev 2005; 14: 1108–12
   PubMed Web of Science ®Google Scholar
• Matos I, Dufloth R, Alvarenga M, et al. p63, cytokeratin 5, and P-cadherin: three molecular markers to distinguish basal phenotype in breast carcinomas. Virchows Arch 2005; 447: 688–94
   PubMed Web of Science ®Google Scholar
• Li H, Cherukuri P, Li N, et al. Nestin is expressed in the basal/myoepithelial layer of the mammary gland and is a selective marker of basal epithelial breast tumors. Cancer Res 2007; 67: 501–10
   PubMed Web of Science ®Google Scholar
• Tang P, Wang J, Bourne P. Molecular classifications of breast carcinoma with similar terminology and different definitions: are they the same?. Hum Pathol 2008; 39: 506–13
   PubMed Web of Science ®Google Scholar
• Olivotto I A, Truong P T, Speers C H, et al. Time to stop progesterone receptor testing in breast cancer management. J Clin Oncol 2004; 22: 1769–70
   PubMed Web of Science ®Google Scholar
• Eichhorn J H. Medullary carcinoma, provocative now as then. Semin Diagn Pathol 2004; 21: 65–73
   PubMed Web of Science ®Google Scholar
• Mullan P B, Millikan R C. Molecular subtyping of breast cancer: opportunities for new therapeutic approaches. Cell Mol Life Sci 2007; 64: 3219–32
   PubMed Web of Science ®Google Scholar
• van de Vijver M J, He Y D, van't Veer L J, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002; 347: 1999–2009
   PubMed Web of Science ®Google Scholar
• West M, Blanchette C, Dressman H, et al. Predicting the clinical status of human breast cancer by using gene expression profiles. Proc Natl Acad Sci USA 2001; 98: 11462–7
   PubMed Web of Science ®Google Scholar
• Chang H Y, Nuyten D S, Sneddon J B, et al. Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. Proc Natl Acad Sci USA 2005; 102: 3738–43
   PubMed Web of Science ®Google Scholar
• Jones C, Nonni A V, Fulford L, et al. CGH analysis of ductal carcinoma of the breast with basaloid/myoepithelial cell differentiation. Br J Cancer 2001; 85: 422–7
   PubMed Web of Science ®Google Scholar
• Seewaldt V L, Scott V. Images in clinical medicine. Rapid progression of basal-type breast cancer. N Engl J Med 2007; 356: e12
   PubMed Web of Science ®Google Scholar
• Luck A A, Evans A J, James J J, et al. Breast carcinoma with basal phenotype: mammographic findings. AJR Am J Roentgenol 2008; 191: 346–51
   PubMed Web of Science ®Google Scholar
• Reis-Filho J S, Milanezi F, Steele D, et al. Metaplastic breast carcinomas are basal-like tumours. Histopathology 2006; 49: 10–21
   PubMed Web of Science ®Google Scholar
• Bertucci F, Finetti P, Cervera N, et al. Gene expression profiling shows medullary breast cancer is a subgroup of basal breast cancers. Cancer Res 2006; 66: 4636–44
   PubMed Web of Science ®Google Scholar
• Fulford L G, Easton D F, Reis-Filho J S, et al. Specific morphological features predictive for the basal phenotype in grade 3 invasive ductal carcinoma of breast. Histopathology 2006; 49: 22–34
   PubMed Web of Science ®Google Scholar
• Tsuda H, Takarabe T, Hasegawa F, et al. Large, central acellular zones indicating myoepithelial tumor differentiation in high-grade invasive ductal carcinomas as markers of predisposition to lung and brain metastases. Am J Surg Pathol 2000; 24: 197–202
   PubMed Web of Science ®Google Scholar
• Kusinska R, Potemski P, Jesionek-Kupnicka D, et al. Immunohistochemical identification of basal-type cytokeratins in invasive ductal breast carcinoma—relation with grade, stage, estrogen receptor and HER2. Pol J Pathol 2005; 56: 107–10
   PubMedGoogle Scholar
• Charafe-Jauffret E, Monville F, Bertucci F, et al. Moesin expression is a marker of basal breast carcinomas. Int J Cancer 2007; 121: 1779–85
   PubMed Web of Science ®Google Scholar
• Savage K, Lambros M B, Robertson D, et al. Caveolin 1 is overexpressed and amplified in a subset of basal-like and metaplastic breast carcinomas: a morphologic, ultrastructural, immunohistochemical, and in situ hybridization analysis. Clin Cancer Res 2007; 13: 90–101
   PubMed Web of Science ®Google Scholar
• Reis-Filho J S, Milanezi F, Paredes J, et al. Novel and classic myoepithelial/stem cell markers in metaplastic carcinomas of the breast. Appl Immunohistochem Mol Morphol 2003; 11: 1–8
   PubMedGoogle Scholar
• Leibl S, Gogg-Kammerer M, Sommersacher A, et al. Metaplastic breast carcinomas: are they of myoepithelial differentiation?: immunohistochemical profile of the sarcomatoid subtype using novel myoepithelial markers. Am J Surg Pathol 2005; 29: 347–53
   PubMed Web of Science ®Google Scholar
• Malzahn K, Mitze M, Thoenes M, et al. Biological and prognostic significance of stratified epithelial cytokeratins in infiltrating ductal breast carcinomas. Virchows Arch 1998; 433: 119–29
   PubMed Web of Science ®Google Scholar
• Evans A J, Rakha E A, Pinder S E, et al. Basal phenotype: a powerful prognostic factor in small screen-detected invasive breast cancer with long-term follow-up. J Med Screen 2007; 14: 210–4
   PubMed Web of Science ®Google Scholar
• Patanaphan V, Salazar O M, Risco R. Breast cancer: metastatic patterns and their prognosis. South Med J 1988; 81: 1109–12
   PubMed Web of Science ®Google Scholar
• Luck A A, Evans A J, Green A R, et al. The influence of basal phenotype on the metastatic pattern of breast cancer. Clin Oncol (R Coll Radiol) 2008; 20: 40–45
   PubMed Web of Science ®Google Scholar
• Hicks D G, Short S M, Prescott N L, et al. Breast cancers with brain metastases are more likely to be estrogen receptor negative, express the basal cytokeratin CK5/6, and overexpress HER2 or EGFR. Am J Surg Pathol 2006; 30: 1097–104
   PubMed Web of Science ®Google Scholar
• Langerod A, Zhao H, Borgan O, et al. TP53 mutation status and gene expression profiles are powerful prognostic markers of breast cancer. Breast Cancer Res 2007; 9: R30
   PubMed Web of Science ®Google Scholar
• Rakha E A, El-Sayed M E, Powe D G, et al. Invasive lobular carcinoma of the breast: Response to hormonal therapy and outcomes. Eur J Cancer 2008; 44: 73–83
   PubMed Web of Science ®Google Scholar
• Laakso M, Tanner M, Nilsson J, et al. Basoluminal carcinoma: a new biologically and prognostically distinct entity between basal and luminal breast cancer. Clin Cancer Res 2006; 12: 4185–91
   PubMed Web of Science ®Google Scholar
• Smith I, Procter M, Gelber R D, et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 2007; 369: 29–36
   PubMed Web of Science ®Google Scholar
• Guarneri V, Broglio K, Kau S W, et al. Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. J Clin Oncol 2006; 24: 1037–44
   PubMed Web of Science ®Google Scholar
• Urruticoechea A, Smith I E, Dowsett M. Proliferation marker Ki-67 in early breast cancer. J Clin Oncol 2005; 23: 7212–20
   PubMed Web of Science ®Google Scholar
• Simon R, Panussis S, Maurer R, et al. KIT (CD117)-positive breast cancers are infrequent and lack KIT gene mutations. Clin Cancer Res 2004; 10: 178–83
   PubMed Web of Science ®Google Scholar
• Tommiska J, Bartkova J, Heinonen M, et al. The DNA damage signalling kinase ATM is aberrantly reduced or lost in BRCA1/BRCA2-deficient and ER/PR/ERBB2-triple-negative breast cancer. Oncogene 2008; 27: 2501–6
   PubMed Web of Science ®Google Scholar
• Umemura S, Yoshida S, Ohta Y, et al. Increased phosphorylation of Akt in triple-negative breast cancers. Cancer Sci 2007; 98: 1889–92
   PubMed Web of Science ®Google Scholar
• Mendelsohn J. Targeting the epidermal growth factor receptor for cancer therapy. J Clin Oncol 2002; 20: 1–13S
   PubMed Web of Science ®Google Scholar
• Mendelsohn J, Baselga J. Epidermal growth factor receptor targeting in cancer. Semin Oncol 2006; 33: 369–85
   PubMed Web of Science ®Google Scholar
• Finn R S, Dering J, Ginther C, et al. Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/“triple-negative” breast cancer cell lines growing in vitro. Breast Cancer Res Treat 2007; 105: 319–26
   PubMed Web of Science ®Google Scholar
• Huang F, Reeves K, Han X, et al. Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: rationale for patient selection. Cancer Res 2007; 67: 2226–38
   PubMed Web of Science ®Google Scholar
• Farmer H, McCabe N, Lord C J, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005; 434: 917–21
   PubMed Web of Science ®Google Scholar
• Bhattacharyya A, Ear U S, Koller B H, et al. The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin. J Biol Chem 2000; 275: 23899–903
   PubMed Web of Science ®Google Scholar
• Kennedy R D, Quinn J E, Mullan P B, et al. The role of BRCA1 in the cellular response to chemotherapy. J Natl Cancer Inst 2004; 96: 1659–68
   PubMed Web of Science ®Google Scholar
• Turner N, Tutt A, Ashworth A. Targeting the DNA repair defect of BRCA tumours. Curr Opin Pharmacol 2005; 5: 388–93
   PubMed Web of Science ®Google Scholar
• De Soto J A, Deng C X. PARP-1 inhibitors: are they the long-sought genetically specific drugs for BRCA1/2-associated breast cancers?. Int J Med Sci 2006; 3: 117–23
   PubMedGoogle Scholar
• Rahman M, Davis S R, Pumphrey J G, et al. TRAIL induces apoptosis in triple-negative breast cancer cells with a mesenchymal phenotype. Breast Cancer Res Treat 2008; Feb 12, (Epub ahead of print)
   Google Scholar